AHM appoints new CEO
AHM is a supplier of speaker program and commercial compliance management solutions for the pharmaceutical industry. Prior to joining AHM, Burgess was the president and CEO of Healthland.
Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy.